CRISPR Therapeutics AG CRSP

CRISPR Therapeutics AG es una empresa suiza de edición genética. Se enfoca en el desarrollo de medicamentos genéticos transformadores para enfermedades graves. La Compañía desarrolla sus productos utilizando la plataforma de edición genética Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, que permite cambios dirigidos precisos en el ácido desoxirribonucleico (ADN) genómico. La Compañía tiene un portafolio de programas terapéuticos en una variedad de áreas de enfermedades, incluyendo hemoglobinopatías, oncología, medicina regenerativa y enfermedades raras. Su principal candidato a producto es CTX001, una terapia de edición genética CRISPR ex vivo para tratar a pacientes que sufren de talasemia beta dependiente de transfusiones o enfermedad grave de células falciformes en la que las células madre hematopoyéticas del paciente son modificadas para producir altos niveles de hemoglobina fetal en glóbulos rojos. La Compañía tiene operaciones comerciales en Londres y el Reino Unido, así como operaciones de investigación y desarrollo en los Estados Unidos.

• Zacks Investment Research 29 sept

  CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

  CRISPR Therapeutics (CRSP) has attracted investor attention with significant revenue growth projections (+771.5% for current fiscal year) and improving earnings estimates. However, the company is rated Zacks Rank #3 (Hold) and trades at a premium valuation (F grade) compared to peers. The stock is expected to perform in line with the broader market in the near term.

  

• GlobeNewswire Inc. 16 sept

  Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

  Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.

  

• GlobeNewswire Inc. 16 sept

  CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand

  The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

  

• The Motley Fool 14 sept

  AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

  The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.

  

• The Motley Fool 11 sept

  Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

  The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.